262 related articles for article (PubMed ID: 22691895)
21. Overactive bladder--a practical approach to evaluation and management.
Madersbacher H
J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
[TBL] [Abstract][Full Text] [Related]
22. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
[TBL] [Abstract][Full Text] [Related]
23. Overactive bladder: diagnosis and management.
Robinson D; Cardozo L
Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
[TBL] [Abstract][Full Text] [Related]
24. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
Kashyap M; Tyagi P
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):617-27. PubMed ID: 23550899
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
27. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
28. Management of OAB in those over age 65.
Natalin R; Lorenzetti F; Dambros M
Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
[TBL] [Abstract][Full Text] [Related]
29. Antimuscarinic mechanisms and the overactive detrusor: an update.
Andersson KE
Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
[TBL] [Abstract][Full Text] [Related]
30. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
Bridgeman MB; Friia NJ; Taft C; Shah M
Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
[TBL] [Abstract][Full Text] [Related]
31. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
32. Emerging drugs for treatment of overactive bladder and detrusor overactivity.
Drake MJ
Expert Opin Emerg Drugs; 2008 Sep; 13(3):431-46. PubMed ID: 18764721
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
Chen HW; Bercik RS; Werner EF; Thung SF
J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
[TBL] [Abstract][Full Text] [Related]
34. The medical management of refractory overactive bladder.
Robinson D; Giarenis I; Cardozo L
Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
[TBL] [Abstract][Full Text] [Related]
35. Mirabegron for overactive bladder.
Belavic JM
Nurse Pract; 2012 Dec; 37(12):9-10. PubMed ID: 23165131
[No Abstract] [Full Text] [Related]
36. Male incontinence: onabotulinum toxin A and sacral nerve stimulation.
Rashid TG; Ockrim JL
Curr Opin Urol; 2013 Nov; 23(6):545-51. PubMed ID: 24080810
[TBL] [Abstract][Full Text] [Related]
37. Overactive bladder.
Carr LK
Can J Urol; 2008 Aug; 15 Suppl 1():32-6; discussion 36. PubMed ID: 18700063
[TBL] [Abstract][Full Text] [Related]
38. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
Chapple CR; Roehrborn CG
Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611
[TBL] [Abstract][Full Text] [Related]
39. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion.
Nitti VW; Kopp Z; Lin AT; Moore KH; Oefelein M; Mills IW
Neurourol Urodyn; 2010 Apr; 29(4):652-7. PubMed ID: 20432330
[TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapy of the overactive bladder.
Andersson KE
Discov Med; 2009 Oct; 8(42):118-24. PubMed ID: 19833057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
